US Patent

US8987262 — Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Method of Use · Assigned to Centre Hospitalier Universitaire de Bordeaux · Expires 2028-10-16 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of a beta blocker, such as propranolol, for treating hemangiomas.

USPTO Abstract

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroÃ¯ds, interferon or vincristine, generally used for the treatment of hemangiomas.

Drugs covered by this patent

propranolol-hydrochloride (PROPRANOLOL HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1988`	—	propranolol-hydrochloride

Patent Metadata

Patent number: US8987262
Jurisdiction: US
Classification: Method of Use
Expires: 2028-10-16
Drug substance claim: No
Drug product claim: No
Assignee: Centre Hospitalier Universitaire de Bordeaux
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.